Coherus BioSciences has confirmed that it has launched its pegfilgrastim biosimilar, Udenyca, in the United States market.
Coherus BioSciences has confirmed that it has launched its pegfilgrastim biosimilar, Udenyca, in the United States market.
In an email to The Center for Biosimilars®, a representative from Coherus confirmed that the California-based biosimilar developer, in keeping with its corporate plans, began sales of the biosimilar on January 3. The company previously announced that it would launch its product at a list price of $4175 per unit, or a 33% discount to the reference pegfilgrastim, Neulasta.
The biosimilar’s list price matches that of Mylan’s Fulphila, the first pegfilgrastim biosimilar to launch in the United States. Despite the fact that Coherus has matched Mylan on list price for the pegfilgrastim product, these prices do not reflect any additional rebates or discounts that the drug makers may offer as a means to differentiate their products in the US marketplace.
Coherus also recently signed a 340B prime vendor program contract with Apexus LLC. Apexus is the Health Resources and Services Administration’s designated prime vendor for the 340B Drug Pricing Program, under which it contracts with nearly all of the 340B-eligible covered entities, and the 340B channel accounts for approximately 35% of the reference pegfilgrastim units sold in the United States. The agreement coincided with Coherus’ receipt of a Q code from CMS and the company’s application of a transitional pass-through payment status for hospital outpatient settings.
With its first biosimilar now launched in the US market, Coherus is now looking to the future. On January 1, Darlene Horton, MD, joined the company as chief medical and regulatory affairs officer.
“We are very pleased that Dr. Horton has joined the executive team at Coherus,” said Denny Lanfear, chairman, president, and CEO of Coherus, in a statement. “She is a foremost biotechnology leader and clinician with an exceptional track record of delivering value to patients and shareholders.”
Among the biosimilar projects that will fall under Horton’s purview in the months ahead are CHS-1420, a proposed adalimumab biosimilar that has completed its phase 3 clinical study in psoriasis; CHS-0214, a proposed etanercept biosimilar that has completed phase 3 clinical studies in both psoriasis and rheumatoid arthritis; CHS-3351, a proposed ranibizumab biosimilar in preclinical development; and CHS-2020, a proposed aflibercept biosimilar in preclinical development.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.